Compare PDLB & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | VYGR |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.1M | 232.4M |
| IPO Year | 2017 | 2015 |
| Metric | PDLB | VYGR |
|---|---|---|
| Price | $16.87 | $4.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 69.1K | ★ 474.3K |
| Earning Date | 01-27-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.83 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $96,252,000.00 | $31,316,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $8.59 | $71.78 |
| P/E Ratio | $18.98 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $10.88 | $2.65 |
| 52 Week High | $16.99 | $6.55 |
| Indicator | PDLB | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 70.16 | 54.46 |
| Support Level | $15.65 | $3.74 |
| Resistance Level | $16.09 | $4.51 |
| Average True Range (ATR) | 0.35 | 0.21 |
| MACD | 0.10 | 0.06 |
| Stochastic Oscillator | 99.72 | 84.94 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.